(VIANEWS) – Celsius Holdings (CELH), OGE Energy Corporation (OGE), Asbury Automotive Group (ABG) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Celsius Holdings (CELH)
42.4% sales growth and 23.23% return on equity
Celsius Holdings, Inc. develops, processes, markets, distributes, and sells functional energy drinks and liquid supplements in the United States, Canadian, European, Middle Eastern, Asia-Pacific, and internationally. The company offers CELSIUS, a fitness drink or supplement designed to accelerate metabolism and burn body fat; various flavors and carbonated and non-carbonated functional energy drinks under the CELSIUS Originals and Vibe name, as well as functional energy drink under the CELSIUS Essentials and CELSIUS On-the-Go Powder names; and CELSIUS ready-to drink products. It distributes its products through direct-to-store delivery, distributors, supermarkets, convenience stores, drug stores, nutritional stores, and mass merchants, as well as health clubs, gyms, the military, and e-commerce websites. The company was formerly known as Vector Ventures, Inc. and changed its name to Celsius Holdings, Inc. in January 2007. Celsius Holdings, Inc. was founded in 2004 and is headquartered in Boca Raton, Florida.
Earnings Per Share
As for profitability, Celsius Holdings has a trailing twelve months EPS of $0.77.
PE Ratio
Celsius Holdings has a trailing twelve months price to earnings ratio of 105.18. Meaning, the purchaser of the share is investing $105.18 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.23%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 46.2% and 58.8%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 95.2%, now sitting on 1.32B for the twelve trailing months.
Moving Average
Celsius Holdings’s worth is way higher than its 50-day moving average of $61.80 and way above its 200-day moving average of $55.47.
Yearly Top and Bottom Value
Celsius Holdings’s stock is valued at $80.99 at 11:22 EST, way below its 52-week high of $91.07 and way higher than its 52-week low of $26.75.
2. OGE Energy Corporation (OGE)
24.1% sales growth and 9.34% return on equity
OGE Energy Corp., together with its subsidiaries, operates as an energy and energy services provider that offers physical delivery and related services in the United States. It operates through Electric Company Operations and Natural Gas Midstream segments. The company generates, transmits, distributes, and sells electric energy. In addition, it provides retail electric service to approximately 889,000 customers, which covers a service area of approximately 30,000 square miles in Oklahoma and western Arkansas; and owns and operates coal-fired, natural gas-fired, wind-powered, and solar-powered generating assets. OGE Energy Corp. was founded in 1902 and is headquartered in Oklahoma City, Oklahoma.
Earnings Per Share
As for profitability, OGE Energy Corporation has a trailing twelve months EPS of $2.07.
PE Ratio
OGE Energy Corporation has a trailing twelve months price to earnings ratio of 16.29. Meaning, the purchaser of the share is investing $16.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.34%.
3. Asbury Automotive Group (ABG)
19.3% sales growth and 19.6% return on equity
Asbury Automotive Group, Inc., together with its subsidiaries, operates as an automotive retailer in the United States. It offers a range of automotive products and services, including new and used vehicles; and vehicle repair and maintenance services, replacement parts, and collision repair services. The company also provides finance and insurance products, including arranging vehicle financing through third parties; and aftermarket products, such as extended service contracts, guaranteed asset protection debt cancellation, prepaid maintenance, and credit life and disability insurance. As of December 31, 2019, the company owned and operated 107 new vehicle franchises representing 31 brands of automobiles at 88 dealership locations; and 25 collision centers in the United States. Asbury Automotive Group, Inc. was founded in 1996 and is headquartered in Duluth, Georgia.
Earnings Per Share
As for profitability, Asbury Automotive Group has a trailing twelve months EPS of $28.75.
PE Ratio
Asbury Automotive Group has a trailing twelve months price to earnings ratio of 7.87. Meaning, the purchaser of the share is investing $7.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.6%.
Yearly Top and Bottom Value
Asbury Automotive Group’s stock is valued at $226.36 at 11:22 EST, way under its 52-week high of $256.39 and way higher than its 52-week low of $178.40.
Revenue Growth
Year-on-year quarterly revenue growth grew by 2.9%, now sitting on 14.8B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Asbury Automotive Group’s EBITDA is 57.15.
4. Eli Lilly and Company (LLY)
19.2% sales growth and 48.44% return on equity
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $5.83.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 129.66. Meaning, the purchaser of the share is investing $129.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 48.44%.
Yearly Top and Bottom Value
Eli Lilly and Company’s stock is valued at $755.90 at 11:22 EST, under its 52-week high of $800.78 and way above its 52-week low of $317.24.
Volume
Today’s last reported volume for Eli Lilly and Company is 758423 which is 75.6% below its average volume of 3109110.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Feb 14, 2024, the estimated forward annual dividend rate is 5.2 and the estimated forward annual dividend yield is 0.68%.
Moving Average
Eli Lilly and Company’s worth is above its 50-day moving average of $688.83 and way higher than its 200-day moving average of $569.79.
5. Steven Madden, Ltd. (SHOO)
11.3% sales growth and 20.57% return on equity
Steven Madden, Ltd. designs, sources, markets, and sells fashion-forward branded and private label footwear, accessories, and apparel for women, men, and children in the United States and internationally. Its Wholesale Footwear segment provides footwear under the Steve Madden, Steven by Steve Madden, Madden Girl, BB Dakota, Dolce Vita, DV Dolce Vita, Betsey Johnson, GREATS, Blondo, Anne Klein, Mad Love, Superga, Madden NYC, and COOL Planet brands, as well as private label footwear. The company's Wholesale Accessories/Apparel segment offers handbags, apparel, small leather goods, belts, soft accessories, fashion scarves, wraps, gifting, and other accessories under the Steve Madden, BB Dakota, Anne Klein, Betsey Johnson, Cejon, Madden NYC, and Dolce Vita brands, as well as private label handbag and accessories to department stores, mass merchants, off-price retailers, online retailers, specialty stores, and independent stores. Its Direct-to-Consumer segment operates Steve Madden and Superga full-price retail stores, Steve Madden outlet stores, and Steve Madden shop-in-shops, as well as digital e-commerce websites, including SteveMadden.com, DolceVita.com, betseyjohnson.com, Blondo.com, GREATS.com, and Superga-USA.com. The company's Licensing segment licenses its Steve Madden, Madden Girl, and Betsey Johnson trademarks. Its First Cost segment operates as a buying agent for footwear products under private labels for national chains, specialty retailers, and value-priced retailers. As of December 31, 2021, it owned and operated 214 brick-and-mortar retail stores that included 147 Steve Madden full-price stores, 66 Steve Madden outlet stores, and 1 Superga store, as well as 6 e-commerce websites. Steven Madden, Ltd. was incorporated in 1990 and is headquartered in Long Island City, New York.
Earnings Per Share
As for profitability, Steven Madden, Ltd. has a trailing twelve months EPS of $2.3.
PE Ratio
Steven Madden, Ltd. has a trailing twelve months price to earnings ratio of 17.62. Meaning, the purchaser of the share is investing $17.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.57%.
6. Franklin Resources (BEN)
8.1% sales growth and 8.43% return on equity
Franklin Resources, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to individuals, institutions, pension plans, trusts, and partnerships. It launches equity, fixed income, balanced, and multi-asset mutual funds through its subsidiaries. The firm invests in the public equity, fixed income, and alternative markets. Franklin Resources, Inc. was founded in 1947 and is based in San Mateo, California with an additional office in Hyderabad, India.
Earnings Per Share
As for profitability, Franklin Resources has a trailing twelve months EPS of $1.9.
PE Ratio
Franklin Resources has a trailing twelve months price to earnings ratio of 14.36. Meaning, the purchaser of the share is investing $14.36 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.43%.
7. Incyte Corporation (INCY)
7.6% sales growth and 12.5% return on equity
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $2.65.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 21.23. Meaning, the purchaser of the share is investing $21.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.5%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Incyte Corporation’s EBITDA is 2.67.
Moving Average
Incyte Corporation’s worth is under its 50-day moving average of $60.74 and below its 200-day moving average of $60.31.
Volume
Today’s last reported volume for Incyte Corporation is 223625 which is 86.68% below its average volume of 1679700.
Yearly Top and Bottom Value
Incyte Corporation’s stock is valued at $56.27 at 11:22 EST, way below its 52-week high of $76.04 and way above its 52-week low of $50.27.
